Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor02
NCT04482309Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in solid tumor, sponsored by AstraZeneca. Started Aug 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04482309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482309.